SK279227B6 - Peptidy s ochrannou aktivitou na organizmus, terap - Google Patents

Peptidy s ochrannou aktivitou na organizmus, terap Download PDF

Info

Publication number
SK279227B6
SK279227B6 SK857-94A SK85794A SK279227B6 SK 279227 B6 SK279227 B6 SK 279227B6 SK 85794 A SK85794 A SK 85794A SK 279227 B6 SK279227 B6 SK 279227B6
Authority
SK
Slovakia
Prior art keywords
pro
peptide
peptides
disorders
gly
Prior art date
Application number
SK857-94A
Other languages
English (en)
Slovak (sk)
Other versions
SK85794A3 (en
Inventor
Predrag Sikiric
Marijan Petek
Sven Seiwerth
Zeljko Grabarevic
Ivo Rotkvic
Marko Duvnjak
Branko Turkovic
Stjepan Mise
Ernest Suchanek
Boris Mildner
Ivan Udovicic
Original Assignee
Predrag Sikiric
Marijan Petek
Sven Seiwerth
Zeljko Grabarevic
Ivo Rotkvic
Marko Duvnjak
Branko Turkovic
Stjepan Mise
Ernest Suchanek
Boris Mildner
Ivan Udovicic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Predrag Sikiric, Marijan Petek, Sven Seiwerth, Zeljko Grabarevic, Ivo Rotkvic, Marko Duvnjak, Branko Turkovic, Stjepan Mise, Ernest Suchanek, Boris Mildner, Ivan Udovicic filed Critical Predrag Sikiric
Publication of SK85794A3 publication Critical patent/SK85794A3/sk
Publication of SK279227B6 publication Critical patent/SK279227B6/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Reproductive Health (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
SK857-94A 1992-11-16 1993-11-16 Peptidy s ochrannou aktivitou na organizmus, terap SK279227B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HR921283 1992-11-16
PCT/EP1993/003217 WO1994011394A2 (en) 1992-11-16 1993-11-16 Peptides with organo-protective activity, process for their preparation and their use in the therapy

Publications (2)

Publication Number Publication Date
SK85794A3 SK85794A3 (en) 1995-01-12
SK279227B6 true SK279227B6 (sk) 1998-08-05

Family

ID=10945833

Family Applications (1)

Application Number Title Priority Date Filing Date
SK857-94A SK279227B6 (sk) 1992-11-16 1993-11-16 Peptidy s ochrannou aktivitou na organizmus, terap

Country Status (17)

Country Link
EP (1) EP0624164B1 (sl)
JP (1) JP2812803B2 (sl)
AT (1) ATE163131T1 (sl)
AU (1) AU5624994A (sl)
BG (1) BG61697B1 (sl)
CA (1) CA2127553C (sl)
CZ (1) CZ285155B6 (sl)
DE (1) DE69316974T2 (sl)
ES (1) ES2114170T3 (sl)
GR (1) GR3026478T3 (sl)
HU (3) HUT67982A (sl)
PL (1) PL304666A1 (sl)
RO (1) RO115733B1 (sl)
RU (1) RU2116311C1 (sl)
SI (1) SI9300595B (sl)
SK (1) SK279227B6 (sl)
WO (1) WO1994011394A2 (sl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA61955C2 (en) * 1997-05-23 2003-12-15 Novel salts of bpc-peptides with organoprojective activity, a process for preparing and use thereof in therapy
SI24318A (sl) * 2013-03-13 2014-09-30 Diagen D.O.O. Nove stabilne soli pentadekapeptida, postopek za njihovo pripravo, njihova uporaba za izdelavo farmacevtskih pripravkov in njihova uporaba v terapiji

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU176089A (sh) * 1989-09-12 1992-09-07 Sikirić, Predrag Postupak za pripremu supstancije bpc i supstancija bpc
DE69219590T2 (de) * 1992-05-30 1997-11-27 Marko Duvnjak BPC-Peptide, deren Herstellung und Verwendung

Also Published As

Publication number Publication date
EP0624164A1 (en) 1994-11-17
ATE163131T1 (de) 1998-02-15
HUT66303A (en) 1994-11-28
EP0624164B1 (en) 1998-02-11
AU5624994A (en) 1994-06-08
DE69316974T2 (de) 1998-07-16
RU2116311C1 (ru) 1998-07-27
WO1994011394A2 (en) 1994-05-26
RU94037232A (ru) 1996-06-20
PL304666A1 (en) 1995-01-09
BG61697B1 (bg) 1998-03-31
BG98907A (bg) 1995-05-31
SK85794A3 (en) 1995-01-12
DE69316974D1 (de) 1998-03-19
WO1994011394A3 (en) 1994-09-15
SI9300595B (sl) 2003-04-30
RO115733B1 (ro) 2000-05-30
HU211260A9 (en) 1995-11-28
HUT67982A (en) 1995-05-29
GR3026478T3 (en) 1998-06-30
SI9300595A (en) 1994-09-30
JP2812803B2 (ja) 1998-10-22
ES2114170T3 (es) 1998-05-16
CA2127553C (en) 2003-01-28
CA2127553A1 (en) 1994-05-26
HU9303247D0 (en) 1994-03-28
HU9401952D0 (en) 1994-09-28
CZ162294A3 (en) 1995-02-15
CZ285155B6 (cs) 1999-05-12
JPH07507568A (ja) 1995-08-24

Similar Documents

Publication Publication Date Title
JP3266311B2 (ja) 新規ポリペプチドおよびこれを用いる抗ｈｉｖ剤
EP0097031B1 (en) Nonapeptide and decapeptide analogs of lhrh useful as lhrh antagonists, their preparation and compositions containing them
EP2875826A1 (en) Composition for preventing or treating sepsis
CA2114313C (en) Bpc peptides, their preparation and use
JPH01305099A (ja) ペプチド誘導体
DE69411342T2 (de) Polypeptid bombesin antagonisten
SK279227B6 (sk) Peptidy s ochrannou aktivitou na organizmus, terap
AU2021200731B2 (en) Pro-drug peptide with improved pharmaceutical properties
AU678917B2 (en) Peptides with organo-protective activity, their preparation and use
AU694701B2 (en) Peptides with organo-protective activity, their preparation and use
US20080280326A1 (en) Novel Gonadotropin-Releasing Hormone, Precursor Peptides Thereof and Genes Encoding the Same
WO2020117081A1 (en) Peptides for use in prevention and treatment of inflammation
NO175102B (no) Analogifremgangsmåte for syntese av tetrapeptidet Ser-Asp-Lys-Pro-OH
JPS59501985A (ja) 生殖腺機能に影響を及ぼすペプチド類
DE4340111A1 (de) Tumor-Nekrose-Faktor-alpha inaktivierende Peptide
JPS6168499A (ja) 新規ペプチド

Legal Events

Date Code Title Description
MM4A Patent lapsed due to non-payment of maintenance fees

Effective date: 20111116